TMCx company receives investment from Houston VC, UH program recognized, and more innovation news

short stories

A TMCx company has raised money in Houston, UH's online program named best in the nation, and more Houston innovation news. Courtesy of TMCx

Houston's innovation ecosystem has seen a busy January so far — the city has claimed a unicorn in High Radius, The Ion has named a series of new execs, and so much more.

Given this influx of news, you might've missed some other Houston innovation headlines, like UH being recognized for its online master's program, recent fundings, and Texas being named a state for female entrepreneurs. Here's a few short stories to catch you up.

Texas Halo Fund invests in TMCx company

Photo via kegg.tech

A medical device company that focuses on keeping its female users in control of their fertility health just received an investment from a Houston venture capital firm.

Texas Halo Fund invested $200K in kegg, a San Francisco-based startup that participated in the Texas Medical Center's TMCx09 cohort. The device is an easy-to-use fertility tracker that easily analyzes cervical fluid to help detect a woman's ovulation up to 7 days in advance. Kegg pairs with a smartphone app to inform and track the user's fertility.

"kegg appeals to us for many reasons. We believe the FemTech space is growing and that women are looking take charge of their fertility. There is an increased desire to have insights into one's health and understanding trends in fertility is a natural progression, says Kyra Doolan, managing Director at Texas Halo Fund, in a news release.

"We've been impressed by the company's CEO Kristina Cahojova and how far she's taken the company with a limited budget. We look forward to seeing the product hit the consumer market."

University of Houston recognized for online graduate program

Photo courtesy of University of Houston

The University of Houston's College of Education's online master's degree programs have been recognized by U.S. News & World Report as among the top in the nation.

The college ranked No. 8 for its program in a ranking that factored in student engagement, technology tools, surveys of deans, faculty credentials, and student excellence, according to a news release from UH.

"Our faculty and staff strive to give students a top-notch experience online," says Bob McPherson, dean of the UH College of Education, in the news release. "We work to emphasize high-quality instruction and support while allowing students the flexibility and personalization of an online learning environment."

UH's program tied for No. 8 with six other schools, but it's still a huge step up from last year's ranking of No. 19.

Texas ranks No. 5 for female entrepreneurs

Getty Images

According to a new ranking from Fit Small Business, Texas is the fifth best state for female entrepreneurs. The Lone Star State is holding strong in the top tier but slipped from its No. 1 ranking last year.

"High start-up growth, no corporate income tax, and a moderate cost of living are all big pluses for the state, but how does it do regarding a friendly women's business and safety climate?" the report reads. "Well, sort of 'middle-of-the-road,' by the numbers we sourced."

Each state was evaluated by four equally weighted factors: its general business climate and opportunity, the number of female-owned businesses, economic and financial health, and safety and well-being for women. Texas's startup climate and opportunity, which was weighted by 35 percent in the study, was ranked No. 4. When it came to economic and financial health, weighted at 15 percent, Texas also snagged the No. 4 spot.

Rice Business Plan Competition startup raises $1.1 million

Photo via resonado.com

Resonado, the runner-up at the 2019 Rice Business Plan Competition, has raised $1.1 million in funding for its thinner, better-sounding speaker system technology.

The company was founded by four University of Notre Dame University classmates — Brian Cho, Christian Femrite, Erik Perez-Perez, and Peter Moeckel.

Rice University's OWL Investment contributed to the round.

Fannin Innovation Studio makes strategic hire

Praveen Kudithipudi

Photo via fannininnovation.com

Praveen Kudithipudi has been named as director of business development at Houston-based Fannin Innovation Studio. He supports the licensing of Fannin's portfolio technologies as well as collaborations with pharmaceutical companies and academic partners.

"I am excited to have a wonderful opportunity to work at Fannin," says Kudithipudi in the news release. "Fannin builds successful life sciences startups while helping to catalyze the formation of a thriving and sustainable life sciences entrepreneurship ecosystem in Houston. The opportunity to lead licensing, diligence, and collaboration efforts with academic institutions and biotechnology companies here in Houston is truly a unique opportunity."

Kudithipudi received his medical degree in India and specialized in neuroscience in the United Kingdom. He received his MBA from New York University. Prior to this role, he worked in banking, venture capital, and investments in New York.

"We are excited to have someone with the range of experiences and caliber of Praveen on the team," says Atul Varadhachary, Fannin managing partner, in the release. "In our business, we look for high potential technologies at an early stage. Having someone with both a medical background and Wall Street know-how is invaluable to us as we review opportunities and reach out to prospective development partners."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings